Le Lézard
Classified in: Health, Business
Subjects: CON, PDT, ACC

Rutherford Health Secures Loan Facility to Drive Forward Proton Beam Therapy

LONDON and NEWPORT, Wales, Oct. 18, 2019 /PRNewswire/ -- Rutherford Health today announced that it has secured a £20million facility with Triple Point Investment Management, the specialist impact investment manager.

The nature of the Impact-Linked Pricing structure means Rutherford can enjoy more favourable loan terms as patient numbers increase at the company's three cancer centres in the UK, which offer proton beam therapy and  a wide range of advanced cancer services.

Mike Moran, chief executive officer, Rutherford Health plc, said:

"We are delighted to have secured this forward thinking facility with Triple Point which shares our goal of widening access to the most advanced cancer treatments. Structuring a loan facility in a way that encourages accessibility to our services is a progressive approach.

"This investment will lead to the continued expansion of our services, particularly proton beam therapy. Triple Point is a proven investment manager committed to delivering social and public good and our services to patients fit extremely well into that ethos."

Steve Gordon, Programme Manager at Triple Point, said:

"Triple Point's first of its kind, Impact-Linked Pricing offering, helps align our goals with those of Rutherford Health in a virtuous circle. Simply put, we are all incentivised to increase access to the cancer treatment centres which, in turn, will trigger more favourable loan terms, which will unlock more resource and accelerate availability even further.

"Triple Point already has extensive experience of investing in impactful technologies on behalf of the UK's public and private sector healthcare providers. We are delighted to play a small part in support of Rutherford's aims to open their world-class treatments to more people in the UK and beyond from their state of the art new facilities."


These press releases may also interest you

at 15:33
PreventionGenetics is excited to announce the availability of their new whole genome sequencing (WGS) test, PGnome®. Prices start at only $2,490 for testing of a single patient. WGS is the ultimate germline DNA test. It is superior to exome and other...

at 15:32
Sustained acoustic medicine (sam®) from ZetrOZ heals a wide range of injuries and relieves the pain caused by them - and the wearable device is covered by personal injury and workers' compensation insurance. The safe and effective treatment...

at 15:21
Boehringer Ingelheim today announced new analyses of the Phase III INBUILD® trial that studied Ofev® (nintedanib) for the treatment of chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype. These analyses were published...

at 15:00
A July 10 article on BBC News reports on the global rise of cosmetic procedures despite the ongoing COVID-19 pandemic. The article reports that as plastic surgeons have tightened health and safety measures in their clinics in response to the health...

at 14:59
Central Texas-based biotechnology startup Industrial Genetics today announces the launch of its proprietary genetic testing technology to identify the virus that causes COVID-19 (SARS-CoV-2), on surfaces and in wastewater. The test, available for use...

at 14:55
Personalized Stem Cells, Inc (PSC), a human adipose-derived stem cell company, has announced that enrollment is officially complete for their FDA approved stem cell clinical trial for  treatment of knee osteoarthritis. 38 patients are participating...

News published on 18 october 2019 at 07:03 and distributed by: